HomeProvidence Medical Technology Inc.

Providence Medical Technology Inc.

Providence Medical Technology Secures $25 Million In Equity Financing

9/20/18: The proceeds of the financing will be used to accelerate commercial expansion and clinical development of its DTRAX® line of cervical fusion instruments designed to help patients suffering from advanced cervical spine conditions.

Providence Medical Technology Announces FDA 510(k) Clearance for DTRAX® Spinal System

5/22/18: "With the FDA 510(k) clearance of DTRAX Spinal System, Providence now has the only sterile-packaged, single-use set of instruments specifically cleared for posterior cervical fusion," said Providence CEO Jeff Smith. "Our unique, single-use instruments assist surgeons in performing the steps of a traditional posterior cervical fusion. We believe DTRAX represents a landmark innovation for cervical fusion benefiting patients, surgeons, facilities, and payers."

Providence Medical Technology Announces Publication of Two New Studies Supporting Tissue-Sparing Posterior Cervical Fusion

7/10/17: In the first study published by Lenzi J, et al. in World Neurosurgery (2017), the authors report results from the first ever prospective, randomized, controlled trial comparing operative results using the DTRAX® Expandable Cage system versus conservative care for patients diagnosed with single-level cervical radiculopathy.